Bladder preservation in older adults with muscle-invasive bladder cancer: A retrospective study with concurrent chemotherapy and twice-daily hypofractionated radiotherapy schedule

Remontet, 2003, Cancer incidence and mortality in France over the period 1978-2000, J Epidemiol Pub Health, 51, 3 Grubmueller, 2016, The treatment of muscle-invasive bladder cancer in geriatric patients, Curr Opin Urol, 26, 160, 10.1097/MOU.0000000000000262 Duquesne, 2011, Vulnerability of the elderly, SFMU Congress; Emergencies, Chapter 28, 283 Aapro, 2011, SIOG (International Society of Geriatric Oncology) recommendations for anthracycline use in the elderly, Hematol Rep, 3 Sogni, 2008, Morbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer, Urology, 71, 919, 10.1016/j.urology.2007.11.125 Froehner, 2009, Complications following radical cystectomy for bladder cancer in the elderly, Eur Urol, 56, 443, 10.1016/j.eururo.2009.05.008 Plouvier, 2020, Impact of age on bladder cancer management practices: a general population study, Acta Oncol, 59, 462, 10.1080/0284186X.2020.1723164 Mohile, 2018, Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology, J Clin Oncol, 36, 2326, 10.1200/JCO.2018.78.8687 Huddart, 2012, Results of the SPARE feasibility study – selective bladder preservation against radical excision in muscle invasive T2/T3 transitional cell carcinoma of the bladder (CRUK/07/011), Int J Radiat Oncol Biol Phys, 84, S119, 10.1016/j.ijrobp.2012.07.211 Kulkarni, G. S., Hermanns, T., Wei, Y., Bhindi, B., Satkunasivam, R., Athanasopoulos, P. et al. Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol Off J Am Soc Clin Oncol, 35(20), 2299–2305. doi:https://doi.org/10.1200/JCO.2016.69.2327. Mohamed, 2018, Trimodalities for bladder cancer in elderly: transurethral resection, hypofractionated radiotherapy and gemcitabine, Cancer Radiother, 22, 236, 10.1016/j.canrad.2017.09.013 Leng, J., Akthar, A. S., Szmulewitz, R. Z., O'Donnell, P. H., Sweis, R. F., Pitroda, S. P. et al. Safety and efficacy of hypofractionated radiotherapy with capecitabine in elderly patients with urothelial carcinoma. Clin Genitourin Cancer, 17(1), e12–e18. doi:https://doi.org/10.1016/j.clgc.2018.10.003. Tran, 2009, Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer, Am J Clin Oncol, 32, 333, 10.1097/COC.0b013e31818b9486 Gergelis, K. R., Kreofsky, C. R., Choo, C. S., Viehman, J., Harmsen, W. S. et al. Outcomes and profiles of older patients receiving definitive radiation therapy for muscle-invasive bladder cancer at a tertiary medical center. Pract Radiat Oncol, 10(5), e378–e387. doi:https://doi.org/10.1016/j.prro.2020.02.008. Turgeon, G. A., Souhami, L., Cury, F. L., Faria, S. L., Duclos, M. et al. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. Int J Radiat Oncol Biol Phys, 88(2), 326–331. doi:https://doi.org/10.1016/j.ijrobp.2013.11.005. Chang, 2017, Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline, J Urol, 198, 552, 10.1016/j.juro.2017.04.086 Housset, M., Maulard, C., Chretien, Y., Dufour, B., Delanian, S. et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol Off J Am Soc Clin Oncol, 11(11), 2150–2157. doi:https://doi.org/10.1200/JCO.1993.11.11.2150. Fabiano, E., Durdux, C., Dufour, B., Mejean, A., Thiounn, N. et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer. Acta Oncol (Stockholm, Sweden), 60(6), 794–802. doi:https://doi.org/10.1080/0284186X.2021.1915498. Sørensen, 1993, Performance status assessment in cancer patients. An inter-observer variability study, Br J Cancer, 67, 773, 10.1038/bjc.1993.140 Koppie, T. M., Serio, A. M., Vickers, A. J., Vora, K., Dalbagni, G. et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer, 112(11), 2384–2392. doi:https://doi.org/10.1002/cncr.23462. Masnoon, 2017, What is polypharmacy? A systematic review of definitions, BMC Geriatr, 17, 230, 10.1186/s12877-017-0621-2 Brorsson, 1984, Katz index of independence in ADL. Reliability and validity in short-term care, Scand J Rehabil Med, 16, 125, 10.2340/165019778416125132 Patry, 2011, Management of malnutrition in the elderly: What has changed since the HAS recommendations in 2007, NPG, 11, 95 Arias, 1997, Radical chemoradiotherapy for elderly patients with bladder carcinoma invading muscle, Cancer., 80, 115, 10.1002/(SICI)1097-0142(19970701)80:1<115::AID-CNCR15>3.0.CO;2-0 Eapen, 2004, Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer, J Urol, 172, 1276, 10.1097/01.ju.0000140456.42509.b6 Boustani, J., Bertaut, A., Galsky, M. D., Rosenberg, J. E., Bellmunt, J., Powles, T. et al. Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Acta Oncol (Stockholm, Sweden), 57(4), 491–497. doi:https://doi.org/10.1080/0284186X.2017.1369565. McPherson, 2017, Chemoradiotherapy in octogenarians as primary treatment for muscle-invasive bladder cancer, Can Urol Assoc J, 11, 24, 10.5489/cuaj.4008 Miyamoto DT, Drumm MR, Clayman RH, Niemierko A, Heney N, Lee R, et al. Outcomes and tolerability of selective bladder preservation by combined modality therapy for invasive bladder cancer in elderly patients. Int J Radiat Oncol Biol Phys 1 oct 2017;99(2): S120. https://doi: https://doi.org/10.1200/JCO.2017.35.6_suppl.316. Christodoulou, M, Reeves, KJ, Hodgson, C et al. Outcomes of radiosensitisation in elderly patients with advanced bladder cancer. Radiother Oncol, 129 (3). pp. 499–506. ISSN 0167-8140. doi:https://doi.org/10.1016/j.radonc.2018.05.022. Hussain, M. H., Glass, T. R., Forman, J., Sakr, W., Smith, D. C., Al-Sarraf, M., Jones, J et al. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol, 165(1), 56–61. doi:https://doi.org/10.1097/00005392-200101000-00014. Kaufman, D. S., Winter, K. A., Shipley, W. U., Heney, N. M., Chetner, M. P., Souhami, L et al. The initial results in muscle-invading bladder cancer of RTOG 95–06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist, 5(6), 471–476. doi:https://doi.org/10.1634/theoncologist.5-6-471. Mak, R. H., Hunt, D., Shipley, W. U., Efstathiou, J. A., Tester, W. J., Hagan, M. P. et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol Off J Am Soc Clin Oncol, 32(34), 3801–3809. doi:https://doi.org/10.1200/JCO.2014.57.5548. Choudhury, A., Porta, N., Hall, E., Song, Y. P., Owen, R., MacKay, R., et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol, 22(2), 246–255. doi:https://doi.org/10.1016/S1470-2045(20)30607-0. Clayman, 2013, Outcomes of selective bladder preservation in the elderly treated with conservative surgery and chemoradiation, Int J Radiat Oncol Biol Phys, 87, S83, 10.1016/j.ijrobp.2013.06.216 Giacalone, N. J., Shipley, W. U., Clayman, R. H., Niemierko, A., Drumm, M., Heney, N. M. et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the massachusetts general hospital experience. Eur Urol, 71(6), 952–960. doi:https://doi.org/10.1016/j.eururo.2016.12.020. Rouprêt Prayer Galetti, T., Soligo, M., Morlacco, A., Lami, V., Nguyen, A., Iafrate, M et al. Morbidity, mortality, and quality assessment following open radical cystectomy in elderly patients with bladder cancer. Aging Clin Exp Res, 33(4), 1049–1061. doi:https://doi.org/10.1007/s40520-020-01613-0. Block, 2017, Intensity modulated radiation therapy in muscle-invasive bladder cancer: predictors of utilization and survival outcomes, Int J RadiatOncol Biol Phys, 99, E215, 10.1016/j.ijrobp.2017.06.1119 Froehner, M., Brausi, M. A., Herr, H. W., Muto, G., & Studer. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol, 56(3), 443–454. doi:https://doi.org/10.1016/j.eururo.2009.05.008. Stangl-Kremser, J., D'Andrea, D., Vartolomei, M., Abufaraj, M., Goldner, G., Baltzer, P. et al. Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder. Urol Oncol, 37(6), 372–379. doi:https://doi.org/10.1016/j.urolonc.2018.11.001. Rödel, C., Grabenbauer, G. G., Kühn, R., Papadopoulos, T., Dunst, J., Meyer, M. et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol Off J Am Soc Clin Oncol, 20(14), 3061–3071. doi:https://doi.org/10.1200/JCO.2002.11.027. Nielsen, M. E., Shariat, S. F., Karakiewicz, P. I., Lotan, Y., Rogers, C. G., Amiel. et al. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol, 51(3), 699–708. doi:https://doi.org/10.1016/j.eururo.2006.11.004. Leveridge, M. J., Siemens, D. R., Mackillop, W. J., Peng, Y., Tannock, I. F., Berman, D. M. et al. Radical cystectomy and adjuvant chemotherapy for bladder cancer in the elderly: a population-based study. Urology, 85(4), 791–798. doi:https://doi.org/10.1016/j.urology.2014.12.027. Turgeon, 2014, Trimodality therapy for bladder preservation in the elderly population with invasive bladder cancer, Front Oncol, 4, 206, 10.3389/fonc.2014.00206 Arcangeli, 2015, A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC), Crit Rev Oncol Hematol, 94, 105, 10.1016/j.critrevonc.2014.11.007 Henningsohn, L., Wijkström, H., Dickman, P. W., Bergmark, K., & Steineck, G. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol, 62(2), 215–225. doi:https://doi.org/10.1016/s0167-8140(01)00455-8. Hoskin, P. J., Rojas, A. M., Saunders, M. I., Bentzen, S. M., Motohashi, K. J., & BCON investigators. Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial. Radiother Oncol, 91(1), 120–125. doi:https://doi.org/10.1016/j.radonc.2008.10.001. James, N. D., Hussain, S. A., Hall, E., Jenkins, P., Tremlett, J., Rawlings, C. et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med, 366(16), 1477–1488. doi:https://doi.org/10.1056/NEJMoa1106106. Shigematsu, 2001, Effect of combined treatment with radiation and low dose etoposide on cell survival, Anticancer Res, 21, 325 Stehman, 1993, Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial, J Clin Oncol, 11, 1523, 10.1200/JCO.1993.11.8.1523 Pfister, C., Gravis, G., Fléchon, A., Soulié, M., Guy, L., Laguerre, B. et al. VESPER Trial Investigators (2021). Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol, 79(2), 214–221. doi:https://doi.org/10.1016/j.eururo.2020.08.024. Flaig, 2020, Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology, J Natl Compr Canc Netw, 18, 329, 10.6004/jnccn.2020.0011 Kaufman, 2000, Oncologist, 5, 471, 10.1634/theoncologist.5-6-471 Keane, 1994, Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model, Cancer Res, 54, 475 Coen, 2019, Bladder preservation with twice-a-day radiation plus fluorouracil/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG/RTOG 0712-a randomized phase II trial, J Clin Oncol Off J Am Soc Clin Oncol, 37, 44, 10.1200/JCO.18.00537 Hussain, 2001, Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study, J Urol, 165, 56, 10.1097/00005392-200101000-00014 Mitin, 2013, Lancet Oncol, 14, 863, 10.1016/S1470-2045(13)70255-9 Caillet, 2011, Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study, J Clin Oncol Off J Am Soc Clin Oncol, 29, 3636, 10.1200/JCO.2010.31.0664 Fonteyne, V., & Sargos, P. What is the optimal dose, fractionation and volume for bladder radiotherapy? Clin Oncol (R Coll Radiol), 33(6), e245–e250. doi:https://doi.org/10.1016/j.clon.2021.03.013.